局灶治疗后机器人辅助根治性前列腺切除术:肿瘤学与功能结局及复发预测因素
这项多中心队列研究纳入82例局灶治疗后前列腺癌复发并接受挽救性机器人辅助根治性前列腺切除术的患者,术后12、24、36个月无进展生存率分别为74%、48%、36%,12个月控尿率为83%,无术中并发症及重大术后并发症。多因素分析显示,野内复发(HR 3.77,95%CI 1.11-12.85;p=0.03)和pT3b分期(HR 5.0,95%CI 1.53-16.39;p=0.008)是复发的独立预测因素。
要点
- 挽救性机器人辅助根治性前列腺切除术后12、24、36个月无进展生存率分别为74%、48%、36%。
- 术后12个月控尿率为83%,无术中并发症及重大术后并发症。
- 野内复发(HR 3.77)和pT3b分期(HR 5.0)是复发的独立预测因素。
核心结论
- 本研究是局灶治疗后挽救性手术的最大系列,显示该术式安全,与初次机器人辅助根治性前列腺切除术相比毒性未增加。
- 野内复发患者似乎具有表型侵袭性疾病,应告知其可能需要多模式治疗。
研究设计与样本
- 多中心队列研究,纳入82例局灶治疗后前列腺癌复发并接受挽救性机器人辅助根治性前列腺切除术的患者。
- 所有患者均有前列腺癌复发的组织学确认,并通过盆腔磁共振成像、骨扫描和/或正电子发射断层扫描/计算机断层扫描排除转移性疾病。
主要发现
- 术后12、24、36个月无进展生存率分别为74%、48%、36%。
- 术后12个月控尿率为83%。
- 无术中并发症,无重大术后并发症。
- 多因素分析中,仅野内复发(HR 3.77,95%CI 1.11-12.85;p=0.03)和pT3b分期(HR 5.0,95%CI 1.53-16.39;p=0.008)是复发的独立预测因素。
临床怎么用
- 作者认为,局灶治疗后识别为野内复发的男性似乎具有表型侵袭性疾病,应告知其可能需要多模式治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are few data on the outcomes and toxicity of radical prostatectomy (RP) among men experiencing local recurrence of prostate cancer (PC) following focal therapy (FT). To characterise perioperative, oncological, and functional outcomes after salvage robot-assisted RP (S-RALP) and determine the risk factors for S-RALP failure, we conducted a multicentre cohort study of 82 patients undergoing S-RALP after FT. All had histological confirmation of PC recurrence, with metastatic disease excluded using pelvic magnetic resonance imaging, a bone scan, and/or positron emission tomography/computed tomography. Progression-free survival was 74%, 48%, and 36% at 12, 24, and 36mo after surgery, respectively. The 12-mo continence rate was 83%. There were no intraoperative complications and no major postoperative complications. On multivariable analysis, only infield recurrence (hazard ratio [HR] 3.77, 95% confidence interval [CI] 1.11-12.85; p=0.03) and pT3b stage (HR 5.0, 95% CI 1.53-16.39; p=0.008) were independent predictors of recurrence. This study represents the largest series of salvage surgery after FT and shows that this approach is safe with no increase in toxicity when compared to primary RALP. Men identified as having infield recurrence after FT appear to have phenotypically aggressive disease and should be counselled regarding the potential need for a multimodal therapeutic approach. PATIENT SUMMARY: Robotic surgery after focal therapy for prostate cancer is safe and achieves postoperative continence results similar to those for robotic radical prostatectomy in treatment-naïve patients. However, if the cancer recurrence is within the previously treated field, the oncological prognosis seems to be worse.
引用
- Marconi L, Stonier T, Tourinho-Barbosa R, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol. 2019. PMID: 30904357. doi:10.1016/j.eururo.2019.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。